Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

What symbol and exchange does Onconetix shares trade?

Onconetix trades on the NASDAQ stock market under the symbol ONCO.

What is Onconetix stock price doing today?

As of November 9, 2026, ONCO stock price declined to $3.69 with 626,080 million shares trading.

What is Onconetix's Beta?

ONCO has a beta of -0.32, meaning it tends to be less sensitive to market movements. ONCO has a correlation of 0.00 to the broad based SPY ETF.

How much is Onconetix worth?

ONCO has a market cap of $2.17 million. This is considered a Sub-Micro Cap stock.

Is Onconetix (ONCO) a good investment?

ONCO has underperformed the market in the last year with a price return of -99.7% while the SPY ETF gained +13.3%. ONCO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -59.2% and -11.7%, respectively, while the SPY returned -1.9% and -1.0%, respectively.

What are the support and resistance levels for Onconetix (ONCO)?

ONCO support price is $5.97 and resistance is $7.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONCO shares will trade within this expected range on the day.